This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Transgender
+3

Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach

Sponsored by Charite University, Berlin, Germany

About this trial

Last updated 2 years ago

Study ID

ChariteU - ECRC XCVD

Status

Recruiting

Type

Observational [Patient Registry]

Placebo

No

Accepting

18-75 Years
18 to 50 Years
All
All

Trial Timing

Started 3 years ago

What is this trial about?

The XCVD study investigates the influence of sex hormones on the composition of the gut microbiome and the possible emergence of cardiovascular risk factors. It will follow 200 healthy transgender individuals for two years during their hormone replacement therapy (HRT) and analyze them for the possible emergence of cardiovascular risk factors in relation to changes in the gut microbiome, metabolome, and immunome. We would also like to phenotype cardiovascular disease.

What are the participation requirements?

Yes

Inclusion Criteria

- Age 18-50

- Language requirements: German, English

- Previous gender hormone replacement therapy (HRT).

- Ability to give consent and written consent to participate.

- Health insurance (for clarification of incidental findings)

No

Exclusion Criteria

- Diseases or functional disorders that, in the opinion of the study physician, preclude participation in the study.

- Incapacity or other circumstances that do not allow study participants to fully understand the nature, significance and scope of this study.

Locations

Location

Status

Recruiting